WELCOME TO The PHARMACEUTICAL REPORT
Q&A with Randy Frisch, CMO at Uberflip
MedAvail | April 01, 2022
MedAvail Holdings, Inc. a technology-enabled retail pharmacy company, announced it has entered into a definitive securities purchase agreement for the sale of common stock and warrants to purchase common stock in a private placement with certain institutional and other accredited investors for gross proceeds to MedAvail of $50 million, before deducting placement agent commissions and other offering expenses.
Pursuant to the terms of the securities purchase agreement and following ...
Boston Scientific | December 02, 2020
Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections.
Fiercepharma | June 04, 2020
The Trump administration unveiled its finalists for Operation Warp Speed on Wednesday afternoon, with a notable Big Pharma bent. Meanwhile, Novavax—whose shot did not make the cut—recruited Japanese manufacturer AGC Biologics to churn out adjuvant for its coronavirus vaccine candidate. And on the heels of a controversial report by the Lancet, the New England Journal of Medicine published data showing hydroxychloroquine didn't do much to prevent infection in people exposed to the ...
Antares Pharma, Inc. | February 04, 2022
Antares Pharma, Inc. a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for TLANDO®, an oral treatment for testosterone replacement therapy. The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act.
TLANDO® was granted tentative approval from the FDA as a twice-daily...
Business Insights, PHARMACY MARKET
Research, PHARMACY MARKET
Research, VIEWS AND ANALYSIS
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE